CARA just announced results from a Ph2/3 trial for its IV pain drug.
The hook is that CARA 's pain and itch treatments are non-opioid and non-addictive.
The problem may be that it does not provide sufficient morphine rescue during the first 16 hours after surgery. It's primary benefit it does not induce vomiting like morphine.
The big question is whether the trial was large enough and confirming enough to receive fast-track designation. (Probably Not)
FMS has licensed CR-835 and paid CARA milestone of $70mn on 5/18.
With this milestone, CARA has a cash runway into 2020.
In addition, CARA's lead program is in Ph3 against Pruritis.
News 
Market Data 
Discover 
